Gufic Biosciences Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, alongside an approval to incorporate a wholly-owned subsidiary in the Philippines. On a consolidated basis, the company reported revenue from operations of Rs. 26,081.80 Lakhs for Q1 FY27, representing a 3.58% increase compared to Rs. 25,181.97 Lakhs in the previous quarter (Q4 FY26) and a 16.58% increase compared to Rs. 22,372.25 Lakhs in the corresponding quarter of the previous year (Q1 FY25). The consolidated net profit for the period stood at Rs. 2,231.28 Lakhs, reflecting a 1.86% increase QoQ from Rs. 2,189.61 Lakhs and a substantial 70.71% increase YoY from Rs. 1,307.04 Lakhs.

Gufic Biosciences Limited is a prominent pharmaceutical company engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations, bulk drugs, and biological products. The company has been expanding its international footprint and technological capabilities, including investments in biological technology platforms and expansion in overseas markets like the Philippines.